Tag Archives: ARIA

Top 10 Biotech Stocks To Own For 2018

Its time for the final push.

With only a handful of trading weeks remaining in 2017, little stands in the way of higher prices.

This years stock market melt-up has produced a long list of incredible winners. The FAANGs, semiconductors, and other big tech stocks have helped fuel the rally. Weve also had multiple chances to profit from the big biotech comeback and the rebirth of homebuilder....More>>>

Hot Biotech Stocks To Invest In 2018

Bio-Techne Corp (NASDAQ:TECH) files its latest 10-K with SEC for the fiscal year ended on June 30, 2017. Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. Bio-Techne Corp has a market cap of $4.5 billion; its shares were traded at around $120.62 with a P/E ratio of 62.16 and P/S ratio of 8.35.....More>>>

Best Biotech Stocks To Buy Right Now

Spark Therapeutics (NASDAQ: ONCE) is a primary gene therapy company to address patients suffering from inherited retinal disease (IRD), hemophilia and neurodegenerative diseases. The company presented the cumulative 1-year follow-up Phase 1/2 data of SPK-9001 infusion for the treatment of hemophilia B and preliminary on SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A at the American....More>>>

Top 5 Biotech Stocks To Watch For 2019

The stock market finished mixed on Tuesday, and although the Dow Jones Industrials still finished with a loss of more than 100 points, other major market benchmarks finished very close to the unchanged level on the day. Geopolitical pressure continued to hurt investor sentiment, and some bad news on the earnings front also cast a pall on trading during the regular session. Yet some stocks managed....More>>>

Top 10 Biotech Stocks To Buy Right Now

The Dow Jones Industrial Average came close to hitting 20,000, but fell short again…nearly four weeks after Barron’s wrote about the possibility in a cover story on Dec. 10.

Getty Images

The S&P 500 rose 0.4% to 2,276.98 today, a record high. The Nasdaq Composite, meanwhile, gained 0.6% to 5,521.06, also a record. The Dow Jones Industrial Average advanced 64.51 points,....More>>>

Top Biotech Stocks To Invest In Right Now

Investment company Harbour Capital Advisors, LLC buys iShares Core MSCI Emerging Markets, iShares Core MSCI EAFE, PIMCO Enhanced Short Maturity Active Exchange-Trad, iShares Nasdaq Biotechnology Index Fund, First Republic Bank, Chubb, Andeavor, Moelis, Charles Schwab Corp, NetEase Inc, sells MetLife Inc, Affiliated Managers Group Inc, Microchip Technology Inc, Nike Inc, Wells Fargo during the 3-months....More>>>

Top 10 Biotech Stocks To Watch For 2018


On Dec. 15, 2017, the share of Omeros Corporation (NASDAQ:OMER) – a bioscience focusing on the innovation and commercialization of drugs to treat complement-mediated diseases, inflammation, and central nervous system disorders – appreciated $0.47 to trade at $19.68 for 3.52% profits (as of 2:47 pm ET). Since we featured the firm in the Integrated BioSci Interview with....More>>>

Top 10 Biotech Stocks To Buy For 2018

Incyte (INCY) spent much of last year being on my attractive but overvalued list, but recent weakness in the biotech sector and other negative company specific factors led to a drastic sell-off. Now that the valuation is depressed, it is time to see if this has become an ROTY opportunity or if there is further downside ahead.

INCY data by YCharts

The year got off to a good start,....More>>>

Top 5 Biotech Stocks To Buy For 2018

The next shoe is set to drop in the high-flying immuno-oncology space, with genetically modified cell therapies close to becoming a reality. As these therapies are forecast to quickly become one of the fastest-growing segments of the $100 billion oncology market in the next few years, investors may want to consider taking a position in this emerging field before the first therapy reaches the market.


Top 10 Biotech Stocks To Buy For 2018

What happened

Shares of Agenus Inc (NASDAQ:AGEN), a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m. EST on Wednesday. Investors weren’t too thrilled about its cancer vaccine’s recent clinical trial failure.

So what

The Prophage G-200 vaccine involved using a patient’s own cancer cells to direct a prolonged immune....More>>>